Re: Squalamine delivery:
The idea of an alternate delivery mechanism for maintenance between IV infusions has some appeal. I.e., patients could receive an initial IV regimen of 25mg/m2/week*4, with maintenance via an alternate delivery mechanism until the next IV infusion.
This kind of hybrid regimen might allow infusions to be spaced at several months instead of one or two months, which would enhance the convenience and attractiveness of Squalamine vis-à-vis the competition.
There may be several potential delivery mechanisms for such maintenance therapy. A pill would be most convenient, of course, but the properties of the molecule may preclude this.
Note: this kind of hybrid treatment regimen, if doable at all, would be something to pursue as a supplement to the lead Squalamine studies using only the IV formulation. Such supplementary studies would not reside on the critical path to FDA approval.
--
biowatch: Why don’t you see what the gurus on the NSTK board think about intranasal delivery of this molecule? T.i.a.
Market Data 
Markets 
AI
